US Product Portfolio

Featured Products

Our product portfolio features several leading products, including Rasuvo®, Metoject®, RupallTM, Gliolan®, and Treosulfan. Through our business development strategy, we are also actively licensing and/or acquiring new products to supplement our growing pipeline.

Medexus Pharma USA RX Products


Rasuvo is a once-weekly, subcutaneous, single-dose auto-injector of methotrexate indicated for the treatment of rheumatoid arthritis, psoriasis and juvenile idiopathic arthritis (JIA).

Learn About Rasuvo


Ixinity [coagulation factor IX (recombinant)] is a medicine used to replace clotting factor (factor IX) that is missing in adults and children at least 12 years of age with hemophilia B.  

Learn About Ixinity

These products may not be right for you. Always read and follow the label.

The contents of this site are for informational purposes only and are not intended, nor should they be used, as a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician, pharmacist or other qualified health care provider with any questions you may have regarding a medical condition and/or the use of these products. Also read the product monograph and/or the consumer information provided with the product.

Portfolio by Growth Phase

Portfolio by Growth Phase

*Percentages are of the Company’s revenue as disclosed in the condensed interim consolidated statements of loss and comprehensive income (unaudited) of the Company for the nine-month period ended December 31, 2019, as filed on SEDAR, plus the pro-forma impact of Ixinity, as if the acquisition had been completed at the beginning of the fiscal year.